Gout

Gout sits in an odd spot in the rating schedule. It's a metabolic disease that attacks joints, but the VA doesn't rate it on its own terms. Under 38 CFR § 4.71a, gout carries diagnostic code 5017, and DC 5017 is rated using the criteria for rheumatoid arthritis at DC 5002. So the entire rating analysis for a gout claim runs through a code written for a different disease. That borrowing is the first thing to understand, because it controls everything that follows.

DC 5002 gives you two completely different ways to be rated, and they don't add together. The first is the active-process method, which rates the disease as an ongoing inflammatory condition based on incapacitating flares, weight loss, anemia, and impairment of health. The second is the chronic-residuals method, which ignores the disease activity and rates the permanent joint damage left behind, on limitation of motion or ankylosis. You get one or the other. The regulation says to assign the higher evaluation, not to combine them. That single rule is where most gout claims get decided, and where a lot of them get decided wrong.

This page walks through DC 5017 and the DC 5002 criteria it borrows, both rating methods and the "higher evaluation, not combined" rule under 38 CFR § 4.14, why flare documentation is the engine of the active-process rating, the C&P exam mechanics, the secondary chain into kidney disease, and the evidence patterns I see across BVA decisions. The remand rate on these cases is high and the exam-inadequacy rate is higher, so the documentation problem is the story.

TL;DR

• Gout is rated under 38 CFR § 4.71a at DC 5017, which is evaluated as rheumatoid arthritis under DC 5002.
• DC 5002 has two separate rating methods: as an active process (based on incapacitating exacerbations, weight loss, anemia, and impairment of health) or on chronic residuals (limitation of motion or ankylosis of the affected joints).
• The two methods are NOT combined. The higher of the two evaluations is assigned. Rating both would be pyramiding under 38 CFR § 4.14.
• The active-process tiers run 20%, 40%, 60%, and 100%, keyed to how often incapacitating flares occur and how badly health is impaired.
• Flare frequency, duration, and incapacitation are the rating drivers under the active-process method. Documentation of attacks is what wins or loses these cases.
• Gout classically attacks the great toe (the first metatarsophalangeal joint), and also the feet, ankles, and knees.
• Secondary chains under 38 CFR § 3.310: gout and chronic kidney disease (urate nephropathy) run together, and gout can be aggravated by diuretics or other medications taken for a service-connected condition.
• In Claim Raven's analysis of 714 BVA gout cases, 42.6% were remanded, 20.3% granted, and 37.1% denied. Of the 530 cases with a C&P adequacy determination, 70.2% had the exam flagged as inadequate.

DC 5017 Is Rated As DC 5002: Why That Matters

The first move in any gout claim is recognizing that DC 5017 doesn't have its own rating criteria. The schedule lists gout in the arthritis group and directs that it be rated under DC 5002, the code for rheumatoid arthritis as an active process. So when a rating decision evaluates a gout claim, it's applying rheumatoid arthritis criteria to a different disease.

That borrowing has a practical consequence. Gout and rheumatoid arthritis behave differently. Rheumatoid arthritis is a chronic, generally symmetric, progressive autoimmune disease. Gout is episodic. It strikes in acute flares, often a single joint at a time, then frequently quiets down between attacks. The active-process criteria at DC 5002 were written with the constant grind of rheumatoid disease in mind, which is why the gout claimant who has dramatic but intermittent attacks has to translate that episodic picture into the language of "exacerbations" and "impairment of health" that the code uses.

The code's two-method structure is what makes this workable. If your gout is in an active inflammatory phase with frequent disabling attacks, the active-process method captures that. If your gout has burned out but left behind damaged joints, deformity, or chronic limited motion, the chronic-residuals method captures that instead. The rater is supposed to look at both and assign whichever produces the higher number.

Method One: Gout As an Active Process

The active-process method rates the disease as an ongoing inflammatory condition. The DC 5002 tiers, as borrowed for gout, read:

100%: Constitutional manifestations associated with active joint involvement, totally incapacitating. 60%: Less than the criteria for 100% but with weight loss and anemia productive of severe impairment of health, or severely incapacitating exacerbations occurring 4 or more times a year or a lesser number over prolonged periods. 40%: Symptom combinations productive of definite impairment of health objectively supported by examination findings, or incapacitating exacerbations occurring 3 or more times a year. 20%: One or two exacerbations a year in a well-established diagnosis.

Read those tiers carefully, because the words doing the work are "exacerbations," "incapacitating," and "impairment of health." The 20% tier is the floor for a well-established gout diagnosis that flares once or twice a year. The 40% tier needs either three or more incapacitating exacerbations a year or definite impairment of health supported by exam findings. The 60% tier needs four or more severely incapacitating exacerbations a year (or fewer over prolonged periods), or weight loss and anemia producing severe impairment of health. The 100% tier requires constitutional manifestations with active joint involvement that is totally incapacitating.

The structure rewards documentation of frequency and severity. A veteran who has six gout attacks a year, each laying them up for several days, is describing a 60%-level picture under the "severely incapacitating exacerbations occurring 4 or more times a year" prong. But the rater can only apply that tier if the attacks are documented as incapacitating. "Patient has a history of gout" does not establish four severely incapacitating exacerbations. Dated records of each attack, with what it disabled and for how long, do.

This is the central tension in gout claims. The disease is episodic, the rating tiers are counted in episodes, and the typical medical record captures attacks only when the veteran happens to be seen during one. Between flares the exam can look unremarkable, and an exam that catches a quiet interval tends to undercount the disease.

Method Two: Chronic Residuals

The second method ignores disease activity and rates what the disease left behind. DC 5002 directs that chronic residuals such as limitation of motion or ankylosis of the affected joints be rated under the appropriate diagnostic codes for the involved joints.

For gout, that means a foot, ankle, or knee damaged by repeated urate attacks gets rated on its limitation of motion or, in severe cases, ankylosis, under the diagnostic code for that joint. A gouty great toe with deformity and limited motion, an ankle with restricted range, a knee that no longer bends fully: each is rated under its own joint code based on the measured loss.

When the joint involvement isn't severe enough to be compensable under a limitation-of-motion code, DC 5003 (degenerative arthritis) provides a fallback, with a minimum rating supported by X-ray evidence of involvement. The note structure under the arthritis codes generally provides that the chronic-residuals path can yield a minimum 10% per major joint group affected, up to a ceiling, when limitation of motion is noncompensable but arthritis is objectively confirmed.

Which method wins depends on the stage of the disease. Early or actively flaring gout usually rates higher under the active-process method, because frequent incapacitating attacks drive the 40% and 60% tiers. Long-standing burned-out gout that no longer flares much but has wrecked the joints usually rates higher on chronic residuals, because the permanent motion loss is what's left. The rater is supposed to compute both and take the larger.

The Rule That Decides These Cases: Higher Evaluation, Not Combined

This is the most important rule on the page. You do not get an active-process rating plus a chronic-residuals rating. DC 5002 instructs that the disease be rated either on the active-process criteria or on the chronic residuals, whichever results in the higher evaluation. Rating it both ways and adding them together would be pyramiding under 38 CFR § 4.14, because both methods are evaluating the same underlying gout.

That cuts in two directions, and veterans need to see both.

It limits stacking. Unlike a knee, where instability and limitation of motion can carry separate ratings, gout under DC 5002 doesn't let you collect for active disease and joint residuals at once. The two methods are alternatives, not additions.

But it also creates an obligation the VA frequently skips. If the rater is supposed to assign the higher of the two evaluations, the rater has to actually evaluate both. A decision that rates the joint residuals at 10% and never computes the active-process picture, or vice versa, has done half the analysis. When a gout claim gets denied or under-rated, one of the first things worth checking is whether the decision considered both methods or quietly picked one and moved on.

There's a related subtlety. Chronic residuals of the same joint can sometimes be rated under separate joint codes if genuinely separate joints are involved (the great toe and the ankle, for example, are different joints), and the active-process rating is a single rating for the disease as a whole. The pyramiding bar is on rating the same disability twice, not on rating two genuinely distinct damaged joints. The line between "the same gout, two ways" (barred) and "two separate joints damaged by gout" (allowed) is where these decisions get argued.

Why Flare Documentation Is the Whole Ballgame

Under the active-process method, the rating is counted in exacerbations. Three or more incapacitating attacks a year reaches 40%. Four or more severely incapacitating attacks a year reaches 60%. So the single most valuable thing in a gout file is a dated, specific record of flares.

What an incapacitating exacerbation looks like in the record: the date it started, which joint, how severe the pain and swelling were, whether the veteran could bear weight or work, what treatment was needed (a course of colchicine, prednisone, an NSAID, an urgent-care or ER visit), and how many days it lasted. A flare that kept the veteran off their feet for four days is incapacitating. A flare mentioned in passing as "occasional gout" tells the rater nothing it can count.

The problem is that gout is treated episodically and often at home. A veteran who knows the drill takes their colchicine, stays off the foot for a few days, and never generates a medical note for that attack. Multiply that across a year and a veteran with eight genuinely incapacitating flares can have a chart that documents one. The rating follows the chart, not the disease, so the undocumented attacks fall out of the count.

This is where the veteran's own contemporaneous documentation does real work. A flare log with dates, the joint involved, pain level, days unable to work or walk, and the medication taken converts an episodic disease into the countable record the 40% and 60% tiers require. Pharmacy refill records for colchicine or prednisone corroborate the frequency. Statements from a spouse or coworker describing the attacks add lay evidence the Board credits. None of this is exotic. It's just the difference between a rateable record and an unrateable one.

Lay testimony matters here because gout flares are observable to a non-expert. The veteran is competent to report that their toe swelled and they couldn't walk, and a spouse is competent to report watching it happen. Under the case law on lay evidence, that testimony is probative as to the frequency and severity of the attacks even when no clinician witnessed them, as long as it's credible and consistent.

C&P Exam Mechanics: What the Examiner Has to Capture

The gout C&P exam is harder to get right than a typical orthopedic exam, and the dataset shows it: of the gout cases with a C&P adequacy determination, 70.2% had the exam flagged as inadequate. That is an unusually high inadequacy rate, and it tracks the structural mismatch between an episodic disease and a one-day exam.

A complete gout exam has to do two jobs because the rating has two methods. For the active-process method, the examiner needs to document the history and frequency of flares, their severity and incapacitation, any constitutional symptoms, weight loss, anemia (which means lab work, not just inspection), and an overall assessment of impairment of health. For the chronic-residuals method, the examiner needs goniometer range-of-motion measurements of the affected joints, notes on any ankylosis or deformity, tophi, and the functional loss in each involved joint.

The exam fails most often in predictable ways. The examiner sees the veteran on a day with no active flare, records normal or near-normal joints, and writes the condition up as quiescent without ever capturing the flare history that drives the active-process tiers. Or the examiner documents the joints but never addresses frequency of exacerbations or impairment of health, leaving the rater unable to apply DC 5002's active-process criteria at all. Or the exam measures range of motion in a single joint and ignores the others gout has touched.

A flare that isn't happening on exam day still counts if the examiner takes a proper history. The examiner is supposed to consider the disease over time, not just the snapshot in front of them, and a gout exam that rates only what's visible in the room on a quiet day is the kind of exam the Board sends back. When the second exam comes back with a real flare history and proper joint measurements, the rating frequently moves.

Secondary Chains: Gout, the Kidneys, and Medication Aggravation

Gout opens two secondary pathways worth knowing, both under 38 CFR § 3.310, which allows service connection for a condition caused or aggravated by a service-connected condition (the aggravation prong comes from Allen v. Brown).

Gout and chronic kidney disease. Gout and the kidneys are biologically linked through uric acid. Chronically elevated urate can deposit in the kidneys and contribute to urate nephropathy and stones, and conversely impaired kidney function raises uric acid and worsens gout, so the two often run together. A veteran with service-connected gout who develops chronic kidney disease has a recognized secondary theory, and the kidney disease rating can be substantial on its own. The nexus opinion has to describe the urate mechanism and the time course, not just assert that the two coexist.

Medication aggravation. This chain runs the other direction and is easy to miss. Diuretics, especially thiazides, raise uric acid and can precipitate or worsen gout. A veteran who takes a diuretic for a service-connected condition (often hypertension or a heart condition) and then develops or worsens gout has an aggravation theory under § 3.310. The same logic applies to other medications that drive up urate. The argument is that the gout was caused or made worse by the treatment for an already-service-connected disability, which makes the gout itself service-connected on a secondary basis even if the underlying metabolic tendency wasn't.

Both chains live or die on the medical opinion. A bare statement that "gout is related to kidney disease" or "the diuretic caused the gout" without the physiological mechanism and a time course isn't probative. An opinion that walks through the uric acid pathway, the medication's known effect on urate, and the chronology carries the case.

Common Evidence Gaps in Gout Claims

A few patterns I see across BVA decisions involving gout.

No countable flare record. The single most common gap. The disease is episodic, the active-process tiers are counted in episodes, and the chart documents a fraction of the attacks because most flares are managed at home. Without dated records of incapacitating exacerbations, the rater can't reach the 40% or 60% tiers no matter how bad the disease actually is. Symptom logs, pharmacy refill records, and lay statements are what fill this gap.

The C&P exam catches a quiet interval. Gout looks fine between flares. An exam on a good day records near-normal joints and undercounts the disease, and because 70.2% of the adjudicated-adequacy cases here had the exam flagged as inadequate, this is not a rare misfire. The fix is an examiner who takes a real flare history rather than rating only what's visible on exam day.

Only one rating method gets considered. DC 5002 requires assigning the higher of the active-process and chronic-residuals evaluations, which means both have to be computed. Decisions routinely rate the joint residuals and never run the active-process math, or vice versa. A decision that considered only one method has done half the analysis.

Missing labs for the higher tiers. The 60% tier references weight loss and anemia productive of severe impairment of health. Anemia is a lab finding. If the exam never ordered or recorded the relevant blood work, the impairment-of-health prongs that support the higher tiers have nothing to stand on.

The kidney and medication secondaries go unclaimed. Veterans with service-connected gout and chronic kidney disease, or with gout that worsened on a diuretic taken for hypertension, often never raise the secondary theory. The conditions sit in the file as unrelated when § 3.310 connects them.

I don't know exactly what share of gout claims have one or more of these gaps. What I can say from Claim Raven's analysis of 714 BVA gout cases is that remands ran at 42.6%, the most common single outcome, denials at 37.1%, and grants at only 20.3%, and that of the 530 cases with a C&P adequacy determination, 70.2% had the exam flagged as inadequate. That pattern is consistent with the documentation problem this page describes. The Board is sending gout cases back for better exams and flare development more often than it's granting them outright, and the low grant rate reflects how often the underlying record fails to capture an episodic disease.

What to Push For

A gout claim is built on two things the typical record lacks: a countable flare history and a complete exam that runs both rating methods.

Document every flare as it happens. Date, joint, severity, days off your feet or out of work, medication taken, and any urgent-care or ER visit. Use a symptom tracker for gout flares to keep a contemporaneous log, because a log written in real time is more credible than a history reconstructed from memory at the exam. Pharmacy refill records for colchicine, prednisone, or allopurinol corroborate the frequency.

Before the C&P exam, prepare to give the examiner the flare history out loud and on paper, because an examiner who only documents the quiet joints in front of them produces an inadequate exam. Use C&P exam prep to organize the frequency, severity, and incapacitation of your attacks, and ask the examiner to address both the active-process picture and the chronic residuals in each affected joint. If anemia or weight loss is part of your picture, make sure the relevant labs are in the record.

When a decision rates only the joint residuals or only the active process, point out that DC 5002 requires assigning the higher of the two and ask for the missing analysis. And run the secondary conditions tool for the kidney and medication chains, with an evidence checklist that separates the active-process proof from the chronic-residuals proof.

Bottom Line

Gout ratings turn on a borrowed code and a choice. DC 5017 is rated as DC 5002, which gives you an active-process method counted in incapacitating exacerbations and a chronic-residuals method rated on the joints gout damaged, and you get the higher of the two, never both. The active-process tiers reward documented flare frequency and severity, which is exactly what an episodic disease managed at home tends not to generate, and the chronic-residuals method picks up the permanent joint loss once the disease has done its damage. The cases I see succeed are the ones with a dated, specific flare record and an exam that takes a real history rather than rating a quiet day. The high remand rate and the 70.2% exam-inadequacy rate in this dataset both point to the same thing: gout is hard to rate from a single snapshot, and the veterans who win are the ones who turn an episodic disease into a countable record before the exam, not after the denial.

Related Conditions

Gout connects to several other pages because the rating mechanics and secondary chains overlap. The DC 5002 framework gout borrows is the same one rheumatoid arthritis is rated under directly, and the chronic-residuals method ties gout to the general arthritis rules at DC 5003. The joints gout most often attacks have their own pages worth reviewing for the limitation-of-motion analysis, including the ankle, the knee, and the foot, where gout often coexists with flat feet. The most important secondary is kidney disease, which runs with gout through uric acid and can carry a substantial rating of its own.

Methodology and Limitations

• Data source: Rating criteria quoted from 38 CFR § 4.71a, DC 5017 (gout) rated as DC 5002 (rheumatoid arthritis). Chronic-residuals fallback under DC 5003. Pyramiding from § 4.14. Secondary service connection from § 3.310. Case law on secondary aggravation from Allen v. Brown.
• Sample size: Patterns in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from the analyzed subset of Claim Raven's 501,000+ Board-decision library, including 714 gout cases. Within that gout subset, outcomes ran 42.6% remanded, 20.3% granted, and 37.1% denied. Of the 530 cases with a C&P adequacy determination, 70.2% had the examination flagged as inadequate. The dataset captures overall outcome rather than a per-method (active-process versus chronic-residuals) breakdown.
• Classification approach: Diagnostic code definitions drawn from the regulatory text. The active-process versus chronic-residuals analysis follows the structure of DC 5002 and the higher-evaluation instruction. Secondary-chain analysis follows § 3.310.
• Limitations:
• Compensation tiers under DC 5002 turn on documented flare frequency and impairment of health, which vary case by case. The dataset does not break out which rating method each decision applied.
• Whether the active-process or chronic-residuals method yields the higher evaluation depends on the stage and severity of the individual veteran's disease.
• The line between rating "the same gout two ways" (barred as pyramiding) and rating two genuinely distinct damaged joints (allowed) is fact-specific and litigated.
• Selection bias: BVA-level patterns reflect cases that appealed. Most gout claims resolve at the RO level and aren't in any BVA dataset.
• Application of the active-process exacerbation criteria at the RO level is uneven, and exam quality varies widely, as the high inadequacy rate reflects.
• These observations reflect patterns from the regulatory text, case law, and BVA decisions. They are not predictions of individual outcomes.